Stimulation of placental prorenin secretion by selective inhibition of cyclic nucleotide phosphodiesterases.
Prorenin secretion by human villous placenta is known to be stimulated by activation of adenylate cyclase and enhanced cyclic AMP (cAMP) generation. Placental tissue contains predominantly type III (cGMP-inhibited) and type IV (cAMP-specific) phosphodiesterases (PDEs), which inactivate cAMP. To evaluate the role of PDE subtypes in the regulation of prorenin secretion by human placenta, explants were cultured in the presence of isobutylmethylxanthine (IBMX), a non-selective PDE inhibitor, and selective inhibitors for various PDE subtypes. Inhibition of PDE subtypes with cilostamide (type III), Ro 20-1724 (type IV) and zardaverine (types III and IV) increased prorenin release. Inhibition of type I (Ca(2+)/calmodulin-dependent) PDE by 8-MeoM-IBMX and of type V (cGMP-specific) PDE by zaprinast or dipyridamole did not affect prorenin secretion. The stimulation of prorenin secretion by PDE inhibitors was attenuated by cAMP-dependent protein kinase inhibition. The selective PDE inhibitors caused a parallel increase in media cAMP and prorenin and also increased tissue prorenin levels. These studies demonstrate that cAMP degradation by type III and IV PDE isoenzymes is a major regulatory mechanism for placental prorenin secretion. It is suggested that enhancers of adenylate cyclase activity are constitutively present in placenta and influence prorenin synthesis and release.
Downing
G J
GJ
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417, USA.
Poisner
A M
AM
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D006063:Chorionic Gonadotropin / Q000032:analysis; D003470:Culture Media / Q000737:chemistry; D046508:Culture Techniques; D000242:Cyclic AMP / Q000032:analysis; D004305:Dose-Response Relationship, Drug; D004789:Enzyme Activation; D004792:Enzyme Precursors / Q000032:analysis*; D006801:Humans; D010920:Placenta / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D011494:Protein Kinases / Q000378:metabolism; D011724:Pyridazines / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D012083:Renin / Q000032:analysis*
D006063:Chorionic Gonadotropin; D003470:Culture Media; D004792:Enzyme Precursors; D011724:Pyridazines; D015363:Quinolones; C021294:cilostamide; D000242:Cyclic AMP; D011494:Protein Kinases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D012083:Renin; D015056:1-Methyl-3-isobutylxanthine; C066436:zardaverine